
A study used Google Cloud Vertex AI to build a no-code AutoML model.
The model classifies bone X-rays as fractured or non-fractured.
Results show promise but need more validation.
What happened
Researchers used Google Cloud Vertex AI to build a no-code AutoML model that classifies bone X-rays as fractured or non-fractured, achieving initial results on a mixed public dataset.
Why it matters
This proof-of-concept demonstrates that non-experts can potentially create AI diagnostic tools, which could help expand access to medical imaging analysis. However, it is a preliminary step, not a ready-to-use clinical tool.
What to watch
Further validation on larger, more diverse datasets is needed before such models can be considered for real-world clinical use.
Ask the AI about this article →
This study addresses the growing interest in making AI accessible to medical professionals without deep technical expertise. By leveraging Google Cloud Vertex AI's no-code interface, the researchers bypassed traditional programming barriers, allowing them to focus on the clinical question. The model's ability to distinguish fractured from non-fractured bones is a critical first step, but the study underscores the need for rigorous validation on diverse patient populations to ensure reliability and safety. Future work should explore larger datasets, different imaging protocols, and potential integration into clinical workflows to assess real-world utility.
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytime
Ask AI anything about this article. Q&As are published on this page for other readers too.
Nucleai announced an ongoing translational research collaboration with Gilead Sciences, using AI-driven tissue…

Gilead Sciences (GILD) has announced an oncology AI deal with Nucleai, a move aimed at strengthening its cance…

Verizon and Google Cloud announced a strategic partnership Monday

American Express is applying an "AI mindset" to drive innovation

Uber's stock dropped after reports that it is capping employee access to AI software, following a budget blowo…

Bristol Myers Squibb (BMS) is partnering with Chai Discovery to use its generative AI for antibody design acro…
